Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus

Cellular Immunology

Volumn 258, Issue 2, 2009, Pages 181-187

  Liu, Lihua ^a   Shan, Baoen ^a   Feng, Yonglu ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; IL 23; Mouse mammary cancer

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 23; INTERLEUKIN 4; PROTEIN P19; PROTEIN P40; PROTEIN SUBUNIT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DNA VECTOR; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNOREGULATION; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SPLEEN CELL; SURVIVAL; UPREGULATION; VIRUS CARCINOGENESIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-12 SUBUNIT P40; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; RETROVIRIDAE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

MURINAE; MUS;

EID: 67649313319     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.05.002     Document Type: Article

References (27)

1. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 260 (1993) 496-497
2. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003) 133-146
3. Bajetta E., Vecchio M., Mortarini R., Nadeau R., Rakhit A., Rimassa L., Fowst C., Borri A., Anichini A., and Parmiani G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res. 4 (1998) 75-78
4. Coughlin C., Wysocka M., Trinchieri G., and Lee W.M. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res. 57 (1997) 2460-2467
5. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh J.K., Zonin F., Vaisberg E., Churakova T., Liu M., Gorman D., Wagner J., Zurawski S., Liu Y., Abrams J.S., Moore K.W., Rennick D., de Waal-Malefyt R., Hannum C., Bazan J.F., and Kastelein R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
6. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J., O'Farrell A.M., McClanahan T., Zurawski S., Hannum C., Gorman D., Rennick D.M., Kastelein R.A., de Waal Malefyt R., and Moore K.W. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168 (2002) 5699-5708
7. Lo C.H., Lee S.C., Wu P.Y., Pan W.Y., Su J., Cheng C.W., Roffler S.R., Chiang B.L., Lee C.N., Wu C.W., and Tao M.H. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171 (2003) 600-607
8. + effector T cells develop via a lineage distint from the T helper type 1 and 2 lineage. Nat. Immunol. 6 (2005) 1123-1132
9. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., and Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6 (2005) 1133-1141
10. Dong C. Diversification of T helper cell lineage: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6 (2006) 329-333
11. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 (2006) 1310-1316
12. Chen Y., Langrish C.L., Mckenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., and Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116 (2006) 1317-1326
13. Kullberg M.C., Jankovic D., Feng C.G., Hue S., Gorelick P.L., McKenzie B.S., Cua D.J., Powrie F., Cheever A.W., Maloy K.J., and Sher A. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203 (2006) 2485-2494
14. Shan B., Yu L., Shimozato O., Li Q., and Tagawa M. Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res. 24 (2004) 79-82
15. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., and Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
16. Belladonna M.L., Renauld J.C., Bianchi R., Vacca C., Fallarino F., Orabona C., Fioretti M.C., Grohmann U., and Puccetti P. IL-23 and IL-12 have overlapping, but distinct, effects on murine dentritic cells. J. Immunol. 168 (2002) 5448-5454
17. Overwijk W.W., Visser K.E., Tirion F.H., Jong L.A., Pols T.W., Velden Y.U., Boorn J.G., Keller A.M., Buurman W.A., Theoret M.R., Blom B., Restifo N.P., Kruisbeek A.M., Kastelein R.A., and Haanen J.B. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176 (2006) 5213-5222
18. Kaiga T., Sato M., Kaneda H., Iwakura Y., Takayama T., and Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178 (2007) 7571-7580
19. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., and Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage-colony stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158 (1997) 3947-3958
20. Manusama E.R., Nooijen P.T., and Stavast J. Synergistic antitumor effect of recombinant human tumor necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br. J. Surg. 83 (1996) 551-555
21. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., Hara I., and Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66 (2006) 6395-6404
22. + T cells. J. Immunol. 173 (2004) 7170-7182
23. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., and Tagawa M. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115 (2005) 437-442
24. Jin H., Youn J., Choi S., Seo S., Park S., Song M., Yang S., and Sung Y. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects. Cancer Gene Ther. 15 (2008) 693-702
25. Liu L., Wang S., Shan B., Shao L., Sato A., Kawamura K., Li Q., Ma G., and Tagawa M. IL-27-mediated activation of natural killer cells and inflammation produced antitumor effects for human esophageal carcinoma cells. Scand. J. Immunol. 68 (2008) 22-29
26. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
27. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188 (1998) 1359-1368